Fanconi anemia (FA) is a recessively inherited syndrome characterized by bone marrow failure, cancer predisposition, and congenital anomalies. FA is a genetically heterogeneous disorder caused by mutations in any of 16 genes which function coordinately to promote DNA repair and prevent apoptosis in response to inflammatory cytokines. Treatment options for marrow failure in FA include androgens and hematopoietic stem cell transplant, but clinical outcomes have been limited by treatment-related toxicities. To address this challenge, this project will investigate and develop alternative medical therapies with greater efficacy and reduced side effects. The mechanism of action of therapeutic agents carries profound implications for FA patient prognosis. Agents that block adaptive stress responses to DNA damage may improve marrow failure but at the risk of promoting the survival of genetically damaged cells which may increase the risk of clonal evolution. Our hypothesis is that compounds that rescue hematopoiesis by protecting from DNA damage provide opportunities to develop safer and more effective therapies to treat marrow failure in Fanconi anemia. The prior funding period of this program project resulted in the identification of several small molecule compounds that improve growth and hematopoiesis in murine models and immortalized cell lines. The molecular mechanism(s) whereby these compounds rescue FA cells will be investigated in Project 1 (PI: Dr. Grompe) and Project 2 (PI: Dr. D'Andrea). Project 3 focuses on evaluating these compounds in primary FA bone marrow cells and FA induced pleuripotent stem cell (iPSC) models (Aim 1) to investigate their effects on hematopoiesis, DNA damage, DNA repair response, and clonal outgrowth. Compounds that rescue hematopoiesis by reducing DNA damage will be prioritized for clinical trial development in Aim 2. Potential biomarkers of DNA damage will be developed for correlative biological studies within the clinical trial. The successful completion with these aims will yield a clinical trial protocol and associated regulatory documents ready to implement by the completion of this project. These agents may be broadly applicable for the treatment of marrow failure in general.

Public Health Relevance

Project 3 Narrative Fanconi anemia is characterized by marrow failure and cancer predisposition. Current therapies are limited and carry toxic side effects. This project will develop new treatments for FA and prepare a clinical trial to test the most promising agents.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-23
Application #
9524786
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Qasba, Pankaj
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
23
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew et al. (2015) Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. Stem Cell Reports 4:90-102
Lombardi, Anne J; Hoskins, Elizabeth E; Foglesong, Grant D et al. (2015) Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21:1962-72

Showing the most recent 10 out of 106 publications